Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Chiara Gasteiger, Alfons A. den Broeder, Sarah Stewart, Norina Gasteiger, Urte Scholz, Nicola Dalbeth & Keith J. Petrie. (2023) The mode of delivery and content of communication strategies used in mandatory and non-mandatory biosimilar transitions: a systematic review with meta-analysis. Health Psychology Review 17:1, pages 148-168.
Read now
Read now
Hemlata Chhabra, Morgane C Mouslim, Smita Kashiramka & Anurag S Rathore. (2022) Dynamics of biosimilar uptake in emerging markets. Expert Opinion on Biological Therapy 22:6, pages 679-688.
Read now
Read now
Peita L Graham-Clarke, Brett Hauber, Marco Boeri, Felice Leonardi, Russel T Burge, Maria Fernandez, Antje Tockhorn-Heidenreich & Sandra Florez. (2020) Patient Preferences for Biologic and Biosimilar Osteoporosis Treatments in Colombia. Patient Preference and Adherence 14, pages 1049-1064.
Read now
Read now
Fabrizio Cantini & Maurizio Benucci. (2018) Focus on biosimilar etanercept – bioequivalence and interchangeability. Biologics: Targets and Therapy 12, pages 87-95.
Read now
Read now
Dae Hyun Yoo, Jung-Yoon Choe, Seung Cheol Shim & Chang-Hee Suh. (2018) Switching to biosimilars in the treatment of rheumatic diseases. Expert Review of Clinical Immunology 14:7, pages 557-571.
Read now
Read now
Articles from other publishers (43)
Allan GibofskyGary JacobsonArchie FranklinShannan O’Hara-LeviLaurent Peyrin-BirouletMelissa McGrathDorothy McCabe. (2023) An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars. Journal of Managed Care & Specialty Pharmacy 29:4, pages 343-349.
Crossref
Crossref
Yoram Bouhnik, Bruno Fautrel, Laurent Beaugerie, Anne-Laure Pelletier, Christine Martinez-Vinson, Ulrich Freudensprung, Amira Brigui & Janet Addison. (2023) PERFUSE: a French non-interventional study of patients with inflammatory bowel disease receiving infliximab biosimilar SB2: a 12-month analysis. Therapeutic Advances in Gastroenterology 16, pages 175628482211456.
Crossref
Crossref
Guillaume Larid, Guy Baudens, Alexis Dandurand, Pascal Coquerelle, Vincent Goeb, Marie Hélène Guyot, Laurent Marguerie, Frédéric Maury, Eric Veillard, Eric Houvenagel, Jean-Hugues Salmon, René-Marc Flipo & Elisabeth Gervais. (2022) Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study. Frontiers in Medicine 9.
Crossref
Crossref
Chiara Gasteiger & Keith J. Petrie. (2022) Moving forward: Implementing health psychology research to improve patient acceptance of biosimilars. Research in Social and Administrative Pharmacy 18:10, pages 3860-3863.
Crossref
Crossref
Fatma Gül Demirkan, Hafize Emine Sönmez, Lovro Lamot, Özlem Akgün, Betül Sözeri & Nuray Aktay Ayaz. (2022) Embracing Change: An International Survey Study on the Beliefs and Attitudes of Pediatric Rheumatologists Towards Biosimilars. BioDrugs 36:3, pages 421-430.
Crossref
Crossref
Liese Barbier, Allary Mbuaki, Steven Simoens, Paul Declerck, Arnold G. Vulto & Isabelle Huys. (2022) Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging. Frontiers in Medicine 9.
Crossref
Crossref
Yannick Vandenplas, Liese Barbier, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto & Isabelle Huys. (2022) Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care. Frontiers in Pharmacology 12.
Crossref
Crossref
Suz Jack Chan, Hui Yee Yeo, Lisa K. Stamp, Gareth J. Treharne & Carlo A. Marra. (2020) What Are the Preferences of Patients With Rheumatoid Arthritis for Treatment Modification? A Scoping Review. The Patient - Patient-Centered Outcomes Research 14:5, pages 505-532.
Crossref
Crossref
Carlos Sánchez-Piedra, Diana Sueiro-Delgado, Javier García-González, Inmaculada Ros-Vilamajo, Agueda Prior-Español, Manuel José Moreno-Ramos, Blanca Garcia-Magallon, Jerusalen Calvo-Gutiérrez, Yanira Perez-Vera, Raquel Martín-Domenech, Dolores Ruiz-Montesino, Paloma Vela-Casasempere, Lorena Expósito, Fernando Sánchez-Alonso, Enrique González-Davila & Federico Díaz-González. (2021) Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years. Scientific Reports 11:1.
Crossref
Crossref
Cristina Martínez-Múgica Barbosa, Belén Rodríguez de Castro, Yoar Labeaga Beramendi, Paloma Terroba Alonso & Javier Barbazán Vázquez. (2021) Patient satisfaction survey: substitution of reference etanercept with a biosimilar product. European Journal of Hospital Pharmacy 28:2, pages 109-111.
Crossref
Crossref
Miguel Ángel Abad Hernández, José Luis Andreu, Alejandro Balsa Criado, Federico Díaz-González, José Vicente Moreno Muelas, Rubén Queiro Silva & Juan J. Gómez-Reino. (2021) Update of the position paper of the Spanish Society of Rheumatology on biosimilar drugs. Reumatología Clínica (English Edition) 17:3, pages 160-169.
Crossref
Crossref
Miguel Ángel Abad Hernández, José Luis Andreu, Alejandro Balsa Criado, Federico Díaz-González, José Vicente Moreno Muelas, Rubén Queiro Silva & Juan J. Gómez-Reino. (2021) Actualización del Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares. Reumatología Clínica 17:3, pages 160-169.
Crossref
Crossref
Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto & Isabelle Huys. (2021) Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. Pharmaceuticals 14:2, pages 117.
Crossref
Crossref
Jinoos Yazdany. (2021) Shifting knowledge and attitudes about biosimilars among rheumatologists. Rheumatology 60:2, pages 492-493.
Crossref
Crossref
Allan Gibofsky & Dorothy McCabe. (2021) US rheumatologists’ beliefs and knowledge about biosimilars: a survey. Rheumatology 60:2, pages 896-901.
Crossref
Crossref
Lynn Weekes. 2020. Biologics, Biosimilars, and Biobetters. Biologics, Biosimilars, and Biobetters
237
251
.
Hye-Jae Lee, Euna Han & Hyero Kim. (2020) Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea. Applied Health Economics and Health Policy 18:4, pages 557-566.
Crossref
Crossref
Kati Sarnola, Merja Merikoski, Johanna Jyrkkä & Katri Hämeen-Anttila. (2020) Physicians’ perceptions of the uptake of biosimilars: a systematic review. BMJ Open 10:5, pages e034183.
Crossref
Crossref
Tom Kovitwanichkanont, Sudha Raghunath, Dorothy Wang, Leo Kyi, Silvana Pignataro, Susan Morton, Eric Morand & Michelle Leech. (2020) Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis. Internal Medicine Journal 50:3, pages 374-377.
Crossref
Crossref
Sarah Costa, Colene Bentley, Dean A. Regier, Helen McTaggart-Cowan, Craig Mitton, Michael M. Burgess & Stuart J. Peacock. (2019) Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs. BMC Public Health 19:1.
Crossref
Crossref
Léa Frantzen, Jean-David Cohen, Sonia Tropé, Morgane Beck, Audrey Munos, Mariannick Sittler, Rita Diebolt, Isabelle Metzler, Laurent Arnaud, Jacques-Éric Gottenberg & Christelle Sordet. (2019) Information et perception des patients au sujet des biosimilaires en rhumatologie. Revue du Rhumatisme 86:6, pages 591-596.
Crossref
Crossref
Filipe César Araújo, João Gonçalves & João Eurico Fonseca. (2019) Biosimilars in rheumatology. Pharmacological Research 149, pages 104467.
Crossref
Crossref
Hans C. Ebbers, Burkhard Pieper, Amine Issa, Janet Addison, Ulrich Freudensprung & Mourad F. Rezk. (2019) Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review. Rheumatology and Therapy 6:3, pages 317-338.
Crossref
Crossref
Rovshan M Ismailov, Zaytuna D Khasanova & Pere Gascon. (2019) Knowledge and awareness of biosimilars among oncology patients in Colorado, USA. Future Oncology 15:22, pages 2577-2584.
Crossref
Crossref
Bente Glintborg, Rikke Ibsen, Rebecca Elisabeth Qwist Bilbo, Merete Lund Hetland & Jakob Kjellberg. (2019) Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis. RMD Open 5:2, pages e001016.
Crossref
Crossref
Léa Frantzen, Jean-David Cohen, Sonia Tropé, Morgane Beck, Audrey Munos, Marie-Annick Sittler, Rita Diebolt, Isabelle Metzler & Christelle Sordet. (2019) Patients’ information and perspectives on biosimilars in rheumatology: A French nation-wide survey. Joint Bone Spine 86:4, pages 491-496.
Crossref
Crossref
Mohammed I. Aladul, Raymond W. Fitzpatrick & Stephen R. Chapman. (2019) The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis. Research in Social and Administrative Pharmacy 15:3, pages 310-317.
Crossref
Crossref
Jason Chau, Thomas Delate, Taylor Ota & Bharati Bhardwaja. (2019) Patient Perspectives on Switching from Infliximab to Infliximab‐dyyb in Patients with Rheumatologic Diseases in the United States. ACR Open Rheumatology 1:1, pages 52-57.
Crossref
Crossref
Bente Glintborg, Anne Gitte Loft, Emina Omerovic, Oliver Hendricks, Asta Linauskas, Jakob Espesen, Kamilla Danebod, Dorte Vendelbo Jensen, Henrik Nordin, Emil Barner Dalgaard, Stavros Chrysidis, Salome Kristensen, Johnny Lillelund Raun, Hanne Lindegaard, Natalia Manilo, Susanne Højmark Jakobsen, Inger Marie Jensen Hansen, Dorte Dalsgaard Pedersen, Inge Juul Sørensen, Lis Smedegaard Andersen, Jolanta Grydehøj, Frank Mehnert, Niels Steen Krogh & Merete Lund Hetland. (2019) To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Annals of the Rheumatic Diseases 78:2, pages 192-200.
Crossref
Crossref
Emily LeonardMichael WascovichSonia OskoueiPaula GurzDelesha Carpenter. (2019) Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review. Journal of Managed Care & Specialty Pharmacy 25:1, pages 102-112.
Crossref
Crossref
Johanna Sigaux, Luca Semerano & Marie-Christophe Boissier. (2019) Faut-il substituer un traitement en cours par un biosimilaire coûte que coûte ?. Revue du Rhumatisme 86:1, pages 1-4.
Crossref
Crossref
Johanna Sigaux, Luca Semerano & Marie-Christophe Boissier. (2018) Switch to a biosimilar: Whatever the cost?. Joint Bone Spine 85:6, pages 651-654.
Crossref
Crossref
Chadi Nabhan, Amy Valley & Bruce A. Feinberg. (2018) Barriers to Oncology Biosimilars Uptake in the United States. The Oncologist 23:11, pages 1261-1265.
Crossref
Crossref
Mohammed Ibrahim Aladul, Raymond William Fitzpatrick & Stephen Robert Chapman. (2018) Healthcare professionals’ perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study. BMJ Open 8:11, pages e023603.
Crossref
Crossref
Johlee S. OdinetChelsea E. DayJennifer L. CruzGregory A. Heindel. (2018) The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies. Journal of Managed Care & Specialty Pharmacy 24:10, pages 952-959.
Crossref
Crossref
Filipe C. Araújo, Joao Eurico Eurico Fonseca & Joao Goncalves. (2018) Switching to Biosimilars in Inflammatory Rheumatic Conditions: Current Knowledge. EMJ Rheumatology, pages 66-74.
Crossref
Crossref
Bente Glintborg, Jan Sørensen & Merete Lund Hetland. (2018) Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis. RMD Open 4:2, pages e000710.
Crossref
Crossref
Jérôme Avouac, Anna Moltó, Vered Abitbol, Adrien Etcheto, Axelle Salcion, Loriane Gutermann, Caroline Klotz, Muriel Elhai, Pascal Cohen, Pierre Antoine Soret, Florence Morin, Ornella Conort, François Chast, Claire Goulvestre, Claire Le Jeunne, Stanislas Chaussade, André Kahan, Christian Roux, Yannick Allanore & Maxime Dougados. (2018) Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. Seminars in Arthritis and Rheumatism 47:5, pages 741-748.
Crossref
Crossref
Akos Ilias, Lorant Gonczi, Zuszsanna Kurti & Peter L. Lakatos. (2018) Biosimilars in ulcerative colitis: When and for who?. Best Practice & Research Clinical Gastroenterology 32-33, pages 35-42.
Crossref
Crossref
Eline van Overbeeke, Birgit De Beleyr, Jan de Hoon, Rene Westhovens & Isabelle Huys. (2017) Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists. BioDrugs 31:5, pages 447-459.
Crossref
Crossref
Mohammed I. Aladul, Raymond W. Fitzpatrick & Stephen R. Chapman. (2017) Patients’ Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey. BioDrugs 31:5, pages 439-446.
Crossref
Crossref
Silvio Danese & Laurent Peyrin-Biroulet. (2017) To switch or not to switch: that is the biosimilar question. Nature Reviews Gastroenterology & Hepatology 14:9, pages 508-509.
Crossref
Crossref
Emma Sullivan, James Piercy, John Waller, Christopher M. Black & Sumesh Kachroo. (2017) Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany. PLOS ONE 12:4, pages e0175826.
Crossref
Crossref